沛嘉医疗-B现涨超3% 董事长于公开市场增持股份 多款产品即将取得重要进展

Core Viewpoint - Peijia Medical (09996) is experiencing a stock price increase, with a current rise of 2.6% to HKD 5.92, and a trading volume of HKD 8.93 million. The company announced that its CEO, Dr. Zhang Yi, will begin purchasing company shares in the open market starting December 1, 2025, with a total investment not exceeding HKD 15 million. This move indicates potential confidence in the company's future performance and growth prospects [1][1][1]. Group 1 - Peijia Medical's CEO, Dr. Zhang Yi, plans to buy company shares in the open market starting December 1, 2025, with an investment cap of HKD 15 million [1][1][1]. - The company's stock has risen over 3%, currently at HKD 5.92, with a trading volume of HKD 8.93 million [1][1][1]. Group 2 - CITIC Securities has reported that Peijia Medical's TAVR products are experiencing continuous growth in volume and steadily increasing market share [1][1][1]. - The GeminiOneTEER system, TaurusTrio aortic regurgitation valve, and TaurusNXT dry valve TAVR are expected to receive intensive approvals between the end of 2025 and 2026, which will drive accelerated growth in the valve business [1][1][1]. - The MonarQ tricuspid valve system has initiated global clinical trials, and the company has secured external financing for its cutting-edge technology, indicating a clear path for innovation and international expansion [1][1][1].